As rumors swirl about Compass Pathways going public, this could become the first psychedelics Unicorn.
As rumors swirl about Compass Pathways going public, this could become the first psychedelics Unicorn.
Champignon Brands has added a new contact research organization (CRO) to advance its IP portfolio.
MindMed begins a Phase 2 clinical trial of LSD for cluster headaches in Switzerland.
AlphaMind Brands Inc is entering the functional mushrooms market.
MindMed has high hopes for its new LSD-based anxiety therapy.
Numinus adds to its management team.
MindMed's Microdosing Division is expanding its ADHD clinical trial.
Certain shareholders have agreed to a voluntary resale restriction that covers 17.8 million shares.
Newly-listed Numinus Wellness provides a corporate update.
MindMed further expands R&D collaboration with University Hospital Basel's Liechti Lab with plans to develop next-gen psychedelic therapies combining LSD and MDMA.
Psychedelics Have Proven Potential To Disrupt Entire Mental Healthcare Industry
Get Your Guide To “Ground Floor” Opportunity In Psychedelic Stocks Now